{rfName}
Di

Indexed in

Documents and Files

jjaa178.pdf

License and Use

Licencia

Citations

48

Altmetrics

Analysis of institutional authors

Veny, MAuthorGarrido-Trigo, AAuthorCorraliza, AmAuthorMasamunt, McAuthorBassolas-Molina, HAuthorEsteller, MAuthorArroyes, MAuthorFernández-Clotet, AAuthorOrdas, IAuthorRicart, EAuthorPanes, JAuthorSalas, ACorresponding Author

Share

September 16, 2020
Publications
>
Article
No

Dissecting common and unique effects of anti-α4β7 and anti-tumor necrosis factor treatment in ulcerative colitis

Publicated to: Journal of Crohns & Colitis. 15 (3): 441-452 - 2021-03-01 15(3), DOI: 10.1093/ecco-jcc/jjaa178

Authors:

Veny, Marisol; Garrido-Trigo, Alba; Corraliza, Ana M; Masamunt, Maria C; Bassolas-Molina, Helena; Esteller, Miriam; Arroyes, Montserrat; Tristan, Eva; Fernandez-Clotet, Agnes; Ordas, Ingrid; Ricart, Elena; Esteve, Maria; Panes, Julian; Salas, Azucena
[+]

Affiliations

‎ Hosp Clin Barcelona, Gastroenterol Dept, Inflammatory Bowel Dis Unit, Barcelona, Spain - Author
‎ Hosp Univ Mutua Terrassa, CIBERehd, Dept Gastroenterol, Terrassa, Spain - Author
‎ Inst Invest Biomed August Pi i Sunyer IDIBAPS, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain - Author
See more

Abstract

Vedolizumab is an anti-?4?7 antibody approved for the treatment of ulcerative colitis (UC). Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the unique mechanisms of action of vedolizumab in UC patients, we compared its effects to those induced by anti-tumor necrosis factor (TNF).Patients with active UC (endoscopic Mayo score >1) starting vedolizumab (n=33) or anti-TNF (n=45) and controls (n=22) were included. Colon biopsies (at weeks 0, 14 and 46) and blood samples (at weeks 0, 2, 6,14, 30 and 46) were used for cell phenotyping, transcriptional analysis (qPCR), and to measure receptor occupancy.Vedolizumab, in contrast to anti-TNF, significantly reduced the proportion of ?4?7 + cells within intestinal T subsets while preserving the percentage of ?4?7 + plasma cells. The marked decrease in ?4?7 did not change the percentage of colonic ?E?7 + cells (at 46 weeks). Both vedolizumab and anti-TNF significantly downregulated inflammation-related genes in the colon of responders (Mayo score <2). Moreover, both treatments significantly decreased the percentage of intestinal, but not blood, total lymphocytes (T and plasma cells), as well as the proportion of ?4?1 + cells within intestinal T lymphocytes.Our data shows that while vedolizumab and anti-TNF block two unrelated targets, they induce remarkably similar effects. On the other hand, vedolizumab's unique mechanism of action relies on blocking intestinal trafficking of ?4?7 T cells, despite effectively binding to B and plasma cells that express ?4?7.© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
[+]

Keywords

?4?1?e?7AdalimumabAdultAlpha 4 beta 1Alpha e beta 7Antibodies, monoclonalAntibodies, monoclonal, humanizedArticleBeta(7) integrinsBiopsyBlood cellBlood samplingCase-control studiesCell-adhesion molecule-1Cohort analysisColitis ulcerosaColitis, ulcerativeColon biopsyColon cellColon, sigmoidControlled studyDigestive system diseasesDown regulationDrug effectDrug mechanismExpressionFemaleGastroenterologíaGastroenterologyGastrointestinal agentsGeneGolimumabHumanHuman cellHuman tissueHumansInflammatory bowel diseaseInflammatory-bowel-diseaseInfliximabIntegrin alpha-4-beta-7IntegrinsLymphocyte countLymphocyte subsetsLymphoid cellMaintenance therapyMajor clinical studyMalalties de l'aparell digestiuMaleMiddle agedMucosalPhenotypePlasma cellsPlasma-cellsPolymerase chain reactionQuantitative analysisReceptor occupancyT lymphocyteT-cellsTumor necrosis factor-alphaUlcerative colitisVedolizumabΑ4β1Αeβ7

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal of Crohns & Colitis due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 12/93, thus managing to position itself as a Q1 (Primer Cuartil), in the category Gastroenterology & Hepatology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.17. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 1.37 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-09, the following number of citations:

  • WoS: 18
  • Scopus: 18
  • Europe PMC: 7
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-09:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 41.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 41 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.
  • The number of mentions on the social network X (formerly Twitter): 4 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Veny Álvarez-Ossorio, Marisol) and Last Author (Salas Martínez, Maria Azucena).

the author responsible for correspondence tasks has been Salas Martínez, Maria Azucena.

[+]

Awards linked to the item

This work was supported by the Agencia de Gestio d'Ajuts Universitaris I de Recerca [AGAUR], Generalitat de Catalunya, Grant 2017SGR992 to A.S. and the Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas [CIBER-EHD], Spain.
[+]

Related Items